Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer
{{output}}
Immune checkpoint inhibitor (ICI) therapy has become a firmly integrated component of the systemic treatment repertoire for locally advanced and metastatic urothelial bladder cancer (UBC). Over the past decade, multiple ICIs have demonstrated meaningful clinic... ...
